Abstract
Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Current Neuropharmacology
Title: Past, Present and Future Therapeutics for Cerebellar Ataxias
Volume: 8 Issue: 1
Author(s): D. Marmolino and M. Manto
Affiliation:
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Abstract: Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Export Options
About this article
Cite this article as:
Marmolino D. and Manto M., Past, Present and Future Therapeutics for Cerebellar Ataxias, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909476
DOI https://dx.doi.org/10.2174/157015910790909476 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Living Heart Valve and Small-Diameter Artery Substitutes - An Emerging Field for Intellectual Property Development
Recent Patents on Biotechnology Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets Multivalent-Based Drug Design Applied to Serotonin 5-HT4 Receptor Oligomers
Current Pharmaceutical Design Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Sauropus androgynus Leaves for Health Benefits: Hype and the Science
The Natural Products Journal Embryonic Stem Cells: A Perfect Marriage Between Gene Regulation and Regenerative Medicine
Current Topics in Medicinal Chemistry Systemic and Biophase Bioavailability and Pharmacokinetics of Nanoparticulate Drug Delivery Systems
Current Drug Delivery How Satiety Factors Reach CNS Appetite Centers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Current Topics in Medicinal Chemistry Review on Hydrate Dissociation Kinetic Behavior
Current Physical Chemistry Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets A Review Study on Prakriti (Body Constitution) Specific Herbal Tea in Diabetes Mellitus
Current Traditional Medicine Changes in Immune and Endocrine Systems in Scrapie-Infected Animals
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Editorial: Current Strategies in Targeting Brain Disorders
CNS & Neurological Disorders - Drug Targets Translational Multimodality Neuroimaging
Current Drug Targets Regulation of Polymorphonuclear Leukocyte-Intestinal Epithelial Cell Interactions: Signalling Events and Potential Drug Targets
Current Signal Transduction Therapy